Claus Bachert, M.D., was the principal investigator of the SINUS-24 and SINUS-52 phase 3 trials, the results of which led to the FDA approval of Dupixent for use with other medicines to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease...
Pin It on Pinterest
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site you consent to our use of cookies.Ok